RedHill Biopharma (RDHL) Common Equity (2011 - 2025)

RedHill Biopharma (RDHL) has 15 years of Common Equity data on file, last reported at $4.3 million in Q4 2025.

• Common Equity for Q4 2025 came in at $4.3 million, up 191.14% year-over-year; the trailing twelve-month figure through Dec 2025 was $4.3 million (up 191.14% YoY), and the FY2025 annual result was $4.3 million, up 191.14% from the prior year.
• Common Equity advanced to $4.3 million in Q4 2025 per RDHL's latest filing, from -$4.7 million in the prior quarter.
• Over five years, Common Equity peaked at $53.0 million in Q1 2021 and troughed at -$48.4 million in Q4 2022.
• A 5-year average of -$570750.0 and a median of $1.1 million in 2023 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2025: Common Equity tumbled 645.35% in 2022, then surged 191.14% in 2025.
• A 5-year view of Common Equity shows it stood at $8.9 million in 2021, then plunged by 645.35% to -$48.4 million in 2022, then jumped by 104.27% to $2.1 million in 2023, then sank by 326.34% to -$4.7 million in 2024, then jumped by 191.14% to $4.3 million in 2025.
• Business Quant data shows RDHL's Common Equity at $4.3 million in Q4 2025, -$4.7 million in Q4 2024, and $61000.0 in Q2 2024.